Literature DB >> 27139621

Myoepithelioma of Soft Tissues: A Single Institution Retrospective Case Series.

Evidio Domingo-Musibay1,2, Andre M Oliveira3, Scott H Okuno2, Ivy A Petersen4, Peter S Rose5, Steven I Robinson2.   

Abstract

BACKGROUND: Myoepithelioma of the soft tissues is a rare entity and little is known about how best to manage locally recurrent and high-grade disease. Here, we retrospectively examined outcomes of surgery, chemotherapy, and radiation therapy (RT) for treatment of low-grade and high-grade myoepithelioma of soft tissues.
METHODS: We reviewed 20 cases of myoepithelioma of soft tissues seen at Mayo Clinic between 1994 and 2014. The effect of histologic grade and therapies received on relapse and survival were assessed.
RESULTS: We identified 13 patients with low-grade disease and 7 patients with high-grade disease. We found that low-grade disease was frequently effectively managed with surgical resection alone, whereas high-grade disease frequently metastasized and was often fatal. The 5-year event-free survival was 88% (confidence interval, 46%-98%) for low-grade disease versus 36% (confidence interval, 7%-75%; P=0.04) for high-grade disease. The relapse rate in low-grade disease was 29% at 5 years versus 64% (P=0.04) in high-grade disease. No significant responses to chemotherapy were noted, however, excellent responses to perioperative RT were seen.
CONCLUSIONS: Surgery continues as the primary modality of treatment for myoepithelioma of soft tissues. Our study did not show a clear benefit of chemotherapy in the metastatic disease setting, but supports the use of perioperative RT in the management of high-grade disease; further investigation is warranted.

Entities:  

Mesh:

Year:  2018        PMID: 27139621     DOI: 10.1097/COC.0000000000000292

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  1 in total

1.  Myoepithelioma of soft tissue in the gluteal region: Diagnostic pitfall in cytology.

Authors:  Viral M Bhanvadia; Neeru M Agarwal; Alpesh D Chavda; Bharat V Bhetariya
Journal:  Cytojournal       Date:  2017-06-20       Impact factor: 2.091

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.